Illumina Q4 Revenues Jump 25 Percent; Forecasts 15 to 17 Percent Growth in 2014 | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina reported after the close of the market on Tuesday that revenues in its fourth quarter increased 25 percent year over year, including a 21 percent bump in product revenues.

The San Diego-based company said that for the last three months of 2013, it took in $387.3 million in total revenues, up from $309.3 million in the year-ago period and besting the average analyst estimate of $382.1 million.

The results were in line with what Illumina had pre-announced earlier this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions. 

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies. 

Mar
17
Sponsored by
Qiagen

This webinar will discuss Qiagen's approach to address two challenges facing NGS in the clinical research setting: lack of seamless workflow for routine clinical research use and truly relevant content to guide clinical research activities.